On this episode of the Talk Radioisotopes podcast, hosts Scott and Sarah are joined by Dr. Shamar Young, Chief Medical Officer at TeleDaaS and Division Chief of Interventional Radiology at the University of Arizona.
The discussion explores Dr. Young’s journey into interventional radiology, his expertise in yttrium-90 (Y90) therapy, and the evolving role of precision dosimetry in radiopharmaceutical treatments. He highlights the challenges of implementing personalized dosimetry, the benefits of outsourcing these services through TeleDaas, and the growing impact of theranostics in cancer care.
Dr. Young also shares insights into patient perceptions of radiation therapy, the rapid advancements in radiopharmaceutical research, and the increasing demand for personalized treatment approaches. The episode wraps up with a look at the future of radiopharmaceuticals, the barriers hospitals face in adopting new treatments, and what’s next for the field over the next five years.
——–
Time Stamps:
*(01:47) Revolutionizing Patient Care
*(04:14) TeleDaaS: Dosimetry as a Service
*(14:03) Patient Perspectives and Misconceptions
*(17:10) Clinical Trials and Future of Radiopharmaceuticals
*(21:59) Challenges and Future Outlook
——–
Links:
Follow Shamar on LinkedIn
Visit TeleDaaS
talkradioisotopes.com
